🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

To those who do not know mathematics it is difficult to get across a real feeling as to the beauty, the deepest beauty, of nature. - Richard Feynman

Did you know actor Adam Driver was once a US Marine? Watch his full talk on bringing theater to the military: t.ted.com/byaYeC6

Today we are thrilled to announce that we're investing almost £1 million into two new research awards which aim to improve the early detection of #PancreaticCancer 🔬

Thank you Pancreatic Cancer UK for This huge support. We are excited in UofG MVLS Jamieson Spatial Lab University of Glasgow to investigate pancreatic cysts with the latest molecular microscopes to better understand why some develop into #pancreaticcancer.

Histotripsy is a noninvasive, nonthermal method for tumor ablation using ultrasound-induced cavitation, offering precise tissue destruction without heat. Learn more in JAMA Surgery's Surgical Innovation article. ja.ma/4hcucDq

MASSIVE Congratulations Lily Hillson PhD on navigating her viva with NO corrections RadNetCRUKGlasgow UofG Cancer Sciences 🎉👏🥂 ‘Characterising dynamic tissue and immune response to RT in #rectalcancer’ Thanks Anna Wilkins The ICR and SimonM for examining. Brilliant day!

Honored to present alongside experts, including our incredible MGH team, on multidisciplinary #cholangiocarcinoma management at #AHPBA2025! Cholangiocarcinoma Foundation Flavio G Rocha, MD, FACS, FSSO Kumar Krishnan Motaz Qadan, MD, PhD Shimul A. Shah

We are so grateful to pts giving their time to participate in research ⁦⁦⁦University of Glasgow⁩ at a hugely stressful time. Even more amazing when pts support research publicity interviewing for national press-Thank you Tracey! scotsman.com/health/scotlan… glasgowtimes.co.uk/news/25049932.…

Published in The Lancet, our review on #PancreaticCancer 📎Epidemiology🌎 📎Pathogenesis🔬 📎Risk factors & surveillance🕵️ 📎Diagnostics🩺 📎Treatment💊 📎Future directions🔍 … by Ammar Asrar Javed, MD PhD 🇺🇸, Atsushi Oba, T. Seufferlein, JW Wilmink, Bas Groot Koerkamp & Marc Besselink

Happening now 🚨 Surgery Working Group 🗣️ Cholangiocarcinoma Foundation Annual Meeting in SLC 🔪 ✂️ 🪡 Determining research priorities for: 1) Classification of resectability 2) Consideration of neoadjuvant therapy 3) Indications for liver transplantation

The potency of abnormal genetic fusion in chronic myeloid leukaemia in our latest study nature 👉🏽 nature.com/articles/s4158… This cancer is an oddity - one of the few single genetic “hit” cancers, a short trajectory (few years) from start to diagnosis, and explosive growth.

Great to catch up with our European surgical 🔪 ✂️🪡 colleagues in #cholangiocarcinoma Cholangiocarcinoma Foundation #ccfac25 🇺🇸 🇬🇧 🇳🇱 🏴󠁧󠁢󠁳󠁣󠁴󠁿 #endcancer

Great to see LauraRosenbergerMD as a world thought leader in #PhyllodesTumor, collaborating with other world experts from the Netherlands Duke Surgical Oncology Duke Surgery Duke Cancer Dutch Phyllodes Group /Contactgroep Phyllodes

#GUTOnline paper by Kemp et al entitled "Tumour-intrinsic alterations and stromal matrix remodelling promote Wnt-niche independence during diffuse-type gastric cancer progression" via bit.ly/42B7gJb colin_wood Nigel B. Jamieson @Gloerichlab #GastricCancer

Excited to announce our first European early access for the Pyxa platform at Dr. @NigelJamieson’s lab, @UniofGlasgow! Together, we’ll explore 3D spatial biology to advance cancer diagnostics & biomarker discovery. bit.ly/4jlYKUd

Elderly colon cancer patients may be able to access a clinical trial that could transform future practice. FOxTROT will test an immunotherapy drug before surgery - the first trial to test the outcomes of this approach in older patients. More ➡️ gla.ac/433duRd

We are excited to be working with Leeds CTRU and Jenny Seligmann on the Foxtrot 5 trial. Improving options for older colon cancer patients and opening up new treatment paradigms! UofG Cancer Sciences

🇬🇧PRIME-RT results ESTRO today: Durvalumab anti-PDL1+SC/LC TNT in #rectalcancer 52% of pts had CR (pCR/cCR) @ 6mth post-EOT in LARC ⬆️CR rate w SCRT-Durv - may reflect divergent immune effects of RT on TME Privileged to be part of incredible ‘Top trials’ session#ESTRO25

The PRIME-RT team comprises fantastic clinical/ CTU teams from across the UK - University of Aberdeen, Oxford The Christie NHS, NHS Ayrshire & Arran and University of Glasgow UofG Cancer Sciences Queen's University Belfast 🎓 We are especially appreciative of the patients who contributed time and energy to be part of the trial.

Next step is translational analysis of serial tumour samples to understand 1. Why tumours respond more or less than others 2. how RT/anti-PDL1 impacts the TME and response evolution. 👀Watch this space Nigel B. Jamieson Joanne Edwards Owen Sansom 🏳️‍🌈 ACRCelerate CRUK Scotland Inst